iREACH Health will host tenants from The HSC, Academia, and Industry
Celerion
Celerion will relocate its U.K. Phase 1 clinical research operations to the facility, positioning it at the forefront of clinical research innovation.
The space will include a 100-bed Phase 1 facility designed to Celerion’s specifications, equipped to support its U.K. team, including a highly experienced full-service data management, medical writing, and biometrics group. This team of early development experts specializes in adaptive study design, protocol development, clinical data sciences, PK/PD analysis, and statistical reporting delivering data-driven insights that reduce risk and optimize trial outcomes.
With over 40 years of global experience in early clinical research—and two decades of work in Northern Ireland—Celerion has established itself as a leader in the field of clinical research and will be the key Industry tenant in iREACH Health.
Known for their speed, innovation, and scientific excellence, Celerion supports biopharmaceutical companies in making faster, more informed decisions about the future of their drug development programmes.
Built on the founding principle that fast, reliable research is critical to a product’s success, Celerion delivers integrated early phase solutions that generate key data more quickly than competitors—empowering clients to make confident go/no-go decisions earlier in the development process.
As one of the world’s premier providers of early stage drug development services, Celerion’s impact is built on experienced leadership, a commitment to operational excellence, and the dedication of their diverse, global team. They are proud to foster an inclusive, supportive workplace that celebrates the unique backgrounds, cultures, and perspectives of their employees.
Celerion’s mission is to help bring life-changing medicines to market—faster. It’s a mission driven by the understanding that every data point generated has the potential to benefit patients, families, and communities around the world.